Search

Your search keyword '"Holland, James F"' showing total 813 results
Start Over Author "Holland, James F"
813 results on '"Holland, James F"'

7. Cardinal Manifestations of Cancer

Author

Holland, James F., primary, Bast, Robert C., additional, Byrd, John C., additional, Croce, Carlo M., additional, Hawk, Ernest T., additional, Khuri, Fadlo R., additional, Pollock, Raphael E., additional, Tsimberadou, Apostolia M., additional, Willett, Christopher G., additional, and Wilman, Cheryl L., additional

Published
2022
Full Text
View/download PDF

16. A Review of Timing Accuracy across the Global Seismographic Network

Author

Ringler, Adam T., primary, Anthony, Robert E., additional, Wilson, David C., additional, Auerbach, Dan, additional, Bargabus, Scott, additional, Davis, Pete, additional, Gunnels, Michael, additional, Hafner, Katrin, additional, Holland, James F., additional, Kearns, Aaron, additional, and Klimczak, Erik, additional

Published
2021
Full Text
View/download PDF

29. Dose Density by Any Other Name

Author

Citron, Marc L., Berry, Donald A., Cirrincione, Constance, Hudis, Clifford, Norton, Larry, Winer, Eric P., Gradishar, William J., Davidson, Nancy E., Martino, Silvana, Livingston, Robert, Ingle, James N., Carpenter, John, Hurd, David, Holland, James F., Smith, Barbara, Sartor, Carolyn I., Leung, Eleanor H., Abrams, Jeffrey, Schilsky, Richard L, and Muss, Hyman B.

Published
2004
Full Text
View/download PDF

33. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Author

Citron, Marc L., Berry, Donald A., Cirrincione, Constance, Hudis, Clifford, Winer, Eric P., Gradishar, William J., Davidson, Nancy E., Martino, Silvana, Livingston, Robert, Ingle, James N., Perez, Edith A., Carpenter, John, Hurd, David, Holland, James F., Smith, Barbara L., Sartor, Carolyn I., Leung, Eleanor H., Abrams, Jeffrey, Schilsky, Richard L., Muss, Hyman B., and Norton, Larry

Published
2003

34. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

Author

Henderson, I. Craig, Berry, Donald A., Demetri, George D., Cirrincione, Constance T., Goldstein, Lori J., Martino, Silvana, Ingle, James N., Cooper, M. Robert, Hayes, Daniel F., Tkaczuk, Katherine H., Fleming, Gini, Holland, James F., Duggan, David B., Carpenter, John T., Frei, Emil, III, Schilsky, Richard L., Wood, William C., Muss, Hyman B., and Norton, Larry

Published
2003

41. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation

Author

Hill, James M., Kornblith, Alice B., Jones, Dana, Freeman, Arnold, Holland, James F., Glicksman, Arvin S., Boyett, James M., Lenherr, Beat, Brecher, Martin L., Dubowy, Ronald, Kung, Faith, Maurer, Harold, and Holland, Jimmie C.

Subjects
Cancer survivors -- Psychological aspects, Methotrexate -- Adverse and side effects, Lymphoblastic leukemia in children -- Psychological aspects, Health
Published
1998

42. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer

Author

Tross, Susan, Herndon, James, II, Korzun, Ann, Kornblith, Alice B., Cella, David F., Holland, James F., Raich, Peter, Johnson, Anita, Kiang, David T., Perloff, Marjorie, Norton, Larry, Wood, William, and Holland, Jimmie C.

Subjects
Breast cancer -- Psychological aspects, Cancer patients -- Patient outcomes, Cancer survivors -- Psychological aspects, Health
Abstract

Background: The possible link between psychological factors and length of cancer survival has generated a literature of contradictory findings. Associations usually have not been found when general psychological symptoms are assessed. Associations usually have been found for predictors related to expressive versus repressive emotional coping (e.g., depression, 'fighting spirit,' hostility, and type C personality); however, even these associations have been relatively small, when compared with those for medical factors. Yet few studies have adequately controlled for medical and treatment-related factors. Purpose: Within a Cancer and Leukemia Group B (CALGB) national clinical trial of four adjuvant therapy regimens for stage 11 breast cancer (CALGB 8082), this study prospectively examined the contribution of potential psychological predictors to length of disease-free and overall survival over a 15-year period. Methods: Subjects were 280 women with stage 11 breast cancer, out of a total of 899, who were randomly assigned to receive CMFVP (cyclophosphamide-methotrexate-fluorouracil-vincristine-prednisone) for two 6-week cycles or six 4-week cycles, then subsequently randomly assigned to receive or not to receive VATH (vinblastine-doxorubicin-thiotepa-fluoxymesterone). Subjects were recruited during the period between October 1980 and August 1984, inclusive, and followed until January 1996. Prior to chemotherapy, psychological symptoms were assessed using the Symptom Check List-90-Revised (SCL-90-R). SCL-90-R scores were trichotomized into categories representing high, medium, and low distress. Basic base-line sociodemographic data (including age, ethnicity, education, and marital status) and medical data (including lymph node status, estrogen receptor status, menopausal status, and performance status) were collected. Subjects with psychosocial data differed from those without psychosocial data solely in their higher percentage of classification in the mild limitation category of the Zubrod (Eastern Cooperative Oncology Group) performance status rating (subjects with psychosocial data: 14%; subjects without psychosocial data: 8%). Results: In stepwise Cox regression analyses that controlled for sociodemographic and medical variables, there was no significant predictive effect of the level of distress (as measured by the SCL-90-R trichotomized scores) on length of disease-free and overall survival of the study subjects. Risk ratios for low versus high distress were 1.01 (95% confidence interval [CI] = .62-1.66) for disease-free survival and 1.03 (95% CI = 0.58-1.82) for overall survival. Conclusions: This study failed to provide evidence that psychological factors contributed to length of disease-free or overall survival of women who received adjuvant chemotherapy (either CMFVP alone or CMFVP followed by VATH) for treatment of stage 11 breast cancer. Implications: In the context of far more potent medical factors, the contribution of psychological factors to disease-free and overall survival is likely to be relatively small. Future research should focus on specific theory-driven predictors rather than on general psychological symptoms. Moreover, it should be based on clinical studies using a controlled, prospective design, in which the effects of medical factors may be distinguished and psychological predictors are clear antecedents of survival outcomes.

Published
1996

43. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer

Author

Runowicz, Carolyn D., Mandeli, John, Speyer, James L., Wadler, Scott, Hochster, Howard, Garrison, Leslie, and Holland, James F.

Subjects
Ovarian cancer, Cyclophosphamide -- Physiological aspects, Carboplatin -- Physiological aspects, Health
Abstract

Ovarian cancer patients undergoing chemotherapy may benefit from a protein treatment that corrects chemotherapy-induced low white cell and platelet counts. Researchers injected the fusion protein PIXY321 into 34 ovarian cancer patients after the second cycle of chemotherapy with cyclophosphamide and carboplatin. The main side effects were redness and hardness at the injection site, and fatigue, fever and loss of appetite. PIXY321 treatments were not effective in increasing white blood cell and platelet counts after multiple cycles of chemotherapy. PIXY321 treatments may be safe and well tolerated by ovarian cancer patients who are also receiving cyclophosphamide and carboplatin. But they may not be able to support larger doses of chemotherapy.

Published
1996

47. Transcription profile of a human breast cancer cell line expressing MMTV-like sequences

Author

Holland James F, Melana Stella M, Fernandez-Cobo Mariana, and Pogo Beatriz GT

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background It has been postulated that inflammation caused by certain viruses might result in cancer. Recently, it was shown that childhood lymphoblastic leukemia, breast and ovarian cancers express an interferon-related signature, providing support for this notion. We have previously shown that 38% of the sporadic breast cancers contain MMTV-like env gene sequences. To find out if the presence and expression of MMTV-like sequences correlated with an inflammatory phenotype, we have compared the expression profile of two sublines of MCF-7 cells, one containing the MMTV-like sequences (env+), the other one lacking them (env-). Results The results indicated that there were 47 differentially expressed genes between the two sublines. Among 27 upregulated genes in the env+ cells there were 7 interferon-related genes, 5 TNF-connected genes and 2 TGFβ-related genes. Conclusion These results suggest that the env+ cells were most likely responding to an infectious agent, and support the hypothesis that a viral infection may play a role in breast cancer pathogenesis.

Published
2006
Full Text
View/download PDF

48. Transcription profiles of non-immortalized breast cancer cell lines

Author

Holland James F, Fernandez-Cobo Mariana, and Pogo Beatriz GT

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Searches for differentially expressed genes in tumours have made extensive use of array technology. Most samples have been obtained from tumour biopsies or from established tumour-derived cell lines. Here we compare cultures of non-immortalized breast cancer cells, normal non-immortalized breast cells and immortalized normal and breast cancer cells to identify which elements of a defined set of well-known cancer-related genes are differentially expressed. Methods Cultures of cells from pleural effusions or ascitic fluids from breast cancer patients (MSSMs) were used in addition to commercially-available normal breast epithelial cells (HMECs), established breast cancer cell lines (T-est) and established normal breast cells (N-est). The Atlas Human Cancer 1.2 cDNA expression array was employed. The data obtained were analysed using widely-available statistical and clustering software and further validated through real-time PCR. Results According to Significance Analysis of Microarray (SAM) and AtlasImage software, 48 genes differed at least 2-fold in adjusted intensities between HMECs and MSSMs (p < 0.01). Some of these genes have already been directly linked with breast cancer, metastasis and malignant progression, whilst others encode receptors linked to signal transduction pathways or are otherwise related to cell proliferation. Fifty genes showed at least a 2.5-fold difference between MSSMs and T-est cells according to AtlasImage, 2-fold according to SAM. Most of these classified as genes related to metabolism and cell communication. Conclusion The expression profiles of 1176 genes were determined in finite life-span cultures of metastatic breast cancer cells and of normal breast cells. Significant differences were detected between the finite life-span breast cancer cell cultures and the established breast cancer cell lines. These data suggest caution in extrapolating information from established lines for application to clinical cancer research.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results